TY - JOUR
T1 - Preformulation studies with melanotan‐II
T2 - A potential skin cancer chemopreventive peptide
AU - Lan, En‐Ling ‐L
AU - Ugwu, Sydney O.
AU - Blanchard, James
AU - Fang, Xiaojun
AU - Hruby, Victor J.
AU - Sharma, Shubh
PY - 1994/8
Y1 - 1994/8
N2 - Melanotan‐II (1) is a cyclic heptapeptide analogue of α‐melanocyte‐stimulating hormone (α‐MSH) which tans the skin and is currently being evaluated for the prevention of sunlight‐induced skin cancers. The dissociation constants of 1 were determined using potentiometric titration and ultraviolet spectrophotometry. The pK a 1, (histidine) and pK a 2 (arginine) were estimated to be 6.54 and 11.72, respectively. The apparent partition coefficient (PC) was measured at three pH values using both n‐octanol and isooctane as the nonpolar phase. The PC(octanol) and Δlog PC at pH 7.35 were 2.82 and 1.05, respectively. These data, together with the observance of a bioavailability of 4.6% in the rat, indicate that 1 may be a suitable candidate for oral delivery. The data presented here are useful in developing an appropriate dosage form for 1.
AB - Melanotan‐II (1) is a cyclic heptapeptide analogue of α‐melanocyte‐stimulating hormone (α‐MSH) which tans the skin and is currently being evaluated for the prevention of sunlight‐induced skin cancers. The dissociation constants of 1 were determined using potentiometric titration and ultraviolet spectrophotometry. The pK a 1, (histidine) and pK a 2 (arginine) were estimated to be 6.54 and 11.72, respectively. The apparent partition coefficient (PC) was measured at three pH values using both n‐octanol and isooctane as the nonpolar phase. The PC(octanol) and Δlog PC at pH 7.35 were 2.82 and 1.05, respectively. These data, together with the observance of a bioavailability of 4.6% in the rat, indicate that 1 may be a suitable candidate for oral delivery. The data presented here are useful in developing an appropriate dosage form for 1.
UR - http://www.scopus.com/inward/record.url?scp=0027968847&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027968847&partnerID=8YFLogxK
U2 - 10.1002/jps.2600830805
DO - 10.1002/jps.2600830805
M3 - Article
C2 - 7983590
AN - SCOPUS:0027968847
SN - 0022-3549
VL - 83
SP - 1081
EP - 1084
JO - Journal of pharmaceutical sciences
JF - Journal of pharmaceutical sciences
IS - 8
ER -